4.3 Article

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Related references

Note: Only part of the references are listed.
Review Cardiac & Cardiovascular Systems

Platelet thrombin receptor antagonism and atherothrombosis

Dominick J. Angiolillo et al.

EUROPEAN HEART JOURNAL (2010)

Review Medicine, General & Internal

Mechanisms of disease:: Platelet activation and atherothrombosis

Giovanni Davi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Prasugrel versus clopidogrel in patients with acute coronary syndromes

Stephen D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Multidisciplinary Sciences

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis

Erik R. Vandendries et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Article Medicine, General & Internal

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

DL Bhatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Article Cardiac & Cardiovascular Systems

Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes

SV Rao et al.

AMERICAN JOURNAL OF CARDIOLOGY (2005)

Article Critical Care Medicine

Thrombin formation

KG Mann

CHEST (2003)

Article Pharmacology & Pharmacy

Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig

Y Kato et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2003)

Review Pharmacology & Pharmacy

Association between aspirin and upper gastrointestinal complications:: Systematic review of epidemiologic studies

LAG Rodríguez et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)